Inventiva S.A. (IVA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Inventiva S.A. (IVA) trades at $3.84 with AI Score 56/100 (Grade B). Inventiva S. A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies. Market cap: $199.61M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026IVA stock analysis for 2026: Analysts have set a consensus price target of $16.50 for Inventiva S.A., suggesting 329.7% upside from the current price of $3.84. The AI MoonshotScore is 56/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
IVA: the 7 perspectives are evenly split. Dominant signal: Ken Griffin bullish.
How is this calculated? →Inventiva S.A. (IVA) Healthcare & Pipeline Overview
Inventiva S.A. is a French clinical-stage biopharmaceutical company specializing in oral small molecule therapies for diseases like NASH and MPS. Their lead candidate, Lanifibranor, is in development for NASH, while strategic collaborations with AbbVie and Boehringer Ingelheim drive innovation in autoimmune diseases and idiopathic pulmonary fibrosis.
What Is the Investment Thesis for IVA?
Inventiva S.A. presents a notable research candidate in the biotechnology sector, driven by its lead candidate Lanifibranor and strategic partnerships. Lanifibranor's potential to address the large and growing NASH market is a key value driver, with Phase III trials expected to commence. The company's collaboration with AbbVie and Boehringer Ingelheim provides financial stability and validation of its research capabilities. However, the company's negative profit margin of -7899.6% highlights the risks associated with clinical-stage biopharmaceutical companies, including the uncertainty of clinical trial outcomes and regulatory approvals. Successful Phase III results for Lanifibranor and further pipeline development are crucial for realizing the company's long-term potential. The company's beta of 0.95 indicates moderate volatility relative to the market.
Based on FMP financials and quantitative analysis
IVA Key Highlights
- Market capitalization of $199.61M reflects investor valuation of Inventiva's pipeline and potential.
- Gross margin of 35.1% indicates the potential profitability of Inventiva's products upon commercialization.
- Lead product candidate Lanifibranor has completed Phase IIb clinical trial for NASH, demonstrating progress in clinical development.
- Strategic collaborations with AbbVie and Boehringer Ingelheim provide financial resources and expertise.
- Focus on oral small molecule therapies offers potential advantages in terms of patient convenience and compliance.
Who Are IVA's Competitors?
IVA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| ICPT Intercept Pharmaceuticals, Inc. | $19.00 | +0.21% | $794.69M | 51 |
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IVA's Key Strengths?
- Lead product candidate Lanifibranor with promising Phase IIb results.
- Strategic collaborations with AbbVie and Boehringer Ingelheim.
- Focus on oral small molecule therapies for patient convenience.
- Experienced management team with expertise in drug development.
What Are IVA's Weaknesses?
- Clinical-stage company with no currently marketed products.
- Negative profit margin and reliance on external funding.
- High risk of clinical trial failure and regulatory setbacks.
- Limited financial resources compared to larger pharmaceutical companies.
What Could Drive IVA Stock Higher?
- Initiation of Phase III clinical trials for Lanifibranor in NASH.
- Potential regulatory updates regarding Lanifibranor's development pathway.
- Progress in strategic collaborations with AbbVie and Boehringer Ingelheim.
- Advancement of earlier-stage programs in oncology and other diseases.
What Are the Key Risks for IVA?
- Financial-distress signal — its Altman Z-Score of -6.34 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure of Phase III clinical trials for Lanifibranor.
- Regulatory delays or rejection of Lanifibranor.
- Competition from other companies developing NASH therapies.
- Dependence on external funding and strategic partnerships.
What Are the Growth Opportunities for IVA?
- Lanifibranor Phase III Trials: The successful completion of Phase III clinical trials for Lanifibranor in NASH represents a significant growth opportunity for Inventiva. Positive trial results could lead to regulatory approval and commercialization, capturing a share of the multi-billion dollar NASH market. The timeline for Phase III completion is estimated to be 2-3 years, with potential market entry by 2029. Competitive advantage lies in Lanifibranor's pan-PPAR agonist mechanism of action.
- Expansion into New Therapeutic Areas: Inventiva can leverage its expertise in drug discovery and development to expand its pipeline into new therapeutic areas beyond NASH and MPS. This could include developing therapies for other fibrotic diseases, autoimmune disorders, or oncology indications. The market size for these indications is substantial, offering significant growth potential. Timeline for new programs to reach clinical stage is estimated at 3-5 years.
- Strategic Partnerships and Collaborations: Continued strategic partnerships with pharmaceutical companies can provide Inventiva with financial resources, expertise, and access to new markets. Collaborations can accelerate the development and commercialization of its pipeline products. The value of these partnerships can range from millions to billions of dollars, depending on the scope and potential of the collaboration.
- Development of Odiparcil for MPS VI: Advancing the development of Odiparcil for MPS VI represents another growth opportunity for Inventiva. MPS VI is a rare genetic disorder with limited treatment options, creating a potential market for Odiparcil. Successful clinical development and regulatory approval could lead to commercialization and revenue generation. The timeline for potential market entry is estimated at 3-4 years.
- Geographic Expansion: Expanding its geographic presence beyond Europe can drive growth for Inventiva. Entering the US market, in particular, represents a significant opportunity, given its large pharmaceutical market and high prevalence of NASH. Establishing a commercial infrastructure in the US or partnering with a US-based company can facilitate market entry. The timeline for US market entry is estimated at 2-3 years following regulatory approval of Lanifibranor.
What Opportunities Does IVA Have?
- Successful completion of Phase III trials for Lanifibranor.
- Expansion into new therapeutic areas and geographic markets.
- Further strategic partnerships and collaborations.
- Growing market for NASH therapies.
What Threats Does IVA Face?
- Competition from other companies developing NASH therapies.
- Regulatory hurdles and delays in drug approval.
- Patent expiration and generic competition.
- Economic downturn and reduced healthcare spending.
What Are IVA's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in oral small molecule drug development.
- Strategic collaborations with established pharmaceutical companies.
- Focus on diseases with unmet medical needs.
What Does IVA Do?
Founded in 2011 and based in Daix, France, Inventiva S.A. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases with significant unmet medical needs. The company focuses on oral small molecule therapies, with a primary emphasis on non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other fibrotic and autoimmune conditions. Inventiva's lead product candidate, Lanifibranor, is a pan-PPAR agonist that has completed a Phase IIb clinical trial for the treatment of NASH, a progressive liver disease affecting millions worldwide. The company is actively preparing for Phase III trials. In addition to Lanifibranor, Inventiva is developing Odiparcil, an oral therapy for MPS VI, which has completed a Phase IIa clinical trial. Inventiva also maintains a pipeline of earlier-stage programs in oncology and other disease areas, leveraging its expertise in drug discovery and development. Strategic collaborations are a key component of Inventiva's business model. The company has partnered with AbbVie to develop and commercialize novel therapies for autoimmune diseases and with Boehringer Ingelheim International GmbH to discover and develop new treatments for idiopathic pulmonary fibrosis (IPF). These collaborations provide Inventiva with financial resources and expertise to advance its research and development programs.
What Products and Services Does IVA Offer?
- Develops oral small molecule therapies.
- Focuses on treating non-alcoholic steatohepatitis (NASH).
- Develops therapies for mucopolysaccharidoses (MPS).
- Conducts clinical trials to evaluate drug candidates.
- Collaborates with pharmaceutical companies for research and development.
- Advances a pipeline of earlier-stage programs in oncology and other diseases.
How Does IVA Make Money?
- Develops and patents novel drug candidates.
- Conducts preclinical and clinical trials to evaluate safety and efficacy.
- Out-licenses or partners with pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
What Industry Does IVA Operate In?
Inventiva S.A. operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The NASH market, in particular, is expected to grow substantially in the coming years, driven by the increasing prevalence of obesity and diabetes. The competitive landscape includes established pharmaceutical companies and other biotech firms developing NASH therapies. Inventiva's strategic collaborations and focus on oral small molecule therapies position it to compete effectively in this dynamic market.
Who Are IVA's Key Customers?
- Patients suffering from NASH.
- Patients suffering from MPS VI.
- Pharmaceutical companies seeking to expand their product portfolios.
- Healthcare providers prescribing treatments for NASH and MPS.
Company Profile
Inventiva S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Daix, FR. The company is led by CEO Andrew Obenshain. IVA has traded publicly since 2020.
F-Score 3/9Financial Health
Inventiva S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.34 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -24.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.1%, the inverse of the P/E and a quick read on earnings relative to price.
IVA Valuation & Market Position
With a $199.61M market cap, Inventiva S.A. sits in the micro-cap segment of the market. Relative to its peer group, IVA's quantitative score of 56/100 is below the peer average of 72/100.
FY2026 estForward Outlook
Wall Street analysts project Inventiva S.A. revenue of about $3.6M for fiscal 2026, with EPS near $-0.67. The estimate reflects 7 contributing analysts.
IVA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting recent advancements in their pipeline and upcoming catalysts.
- Analysts have noted a favorable response to recent clinical trial results, boosting optimism among investors and stakeholders alike.
- The company's strategic partnerships have been well-received, enhancing its credibility and potential for growth in the biopharmaceutical sector.
Bear Case
- Concerns linger over the company's cash runway, with some investors worried about its ability to fund ongoing projects without additional financing.
- Negative sentiment has emerged around potential regulatory hurdles that could delay product launches, impacting investor confidence.
- Recent social media discussions reveal skepticism about the scalability of their current offerings, leading to doubts about long-term viability.
- Market perception has been mixed, with some analysts cautioning against overvaluation based on recent hype rather than solid fundamentals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IVA Latest News
IVA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IVA.
Price Targets
Consensus target: $16.50
IVA MoonshotScore
What does this score mean?
The MoonshotScore rates IVA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Nazira Amra
CEO
Nazira Amra is the CEO of Inventiva S.A. Her background includes extensive experience in the pharmaceutical and biotechnology industries. She has held leadership positions in various companies, focusing on strategic development, commercialization, and business operations. Her expertise spans across multiple therapeutic areas, including metabolic diseases and oncology. She brings a wealth of knowledge in driving innovation and growth within the biopharmaceutical sector.
Track Record: Under Nazira Amra's leadership, Inventiva S.A. has advanced its lead product candidate, Lanifibranor, through Phase IIb clinical trials for NASH. She has also secured strategic collaborations with AbbVie and Boehringer Ingelheim, strengthening the company's financial position and pipeline development. Her focus on innovation and strategic partnerships has been instrumental in driving Inventiva's growth and development.
Inventiva S.A. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company's stock, allowing U.S. investors to trade the shares on American stock exchanges. For Inventiva S.A. (IVA), the ADR represents ownership in the French company, simplifying investment for U.S. investors without directly dealing with foreign markets.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 2
- ADR Ratio: 1:1
Common Questions About IVA (Healthcare)
What does Inventiva S.A. do?
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for diseases with significant unmet medical needs. Its lead product candidate, Lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease. The company also has a pipeline of other drug candidates in development for mucopolysaccharidoses (MPS) and other diseases. Inventiva's business model involves discovering, developing, and partnering with pharmaceutical companies to commercialize its therapies.
What do analysts say about IVA stock?
Analyst coverage of Inventiva S.A. is limited, reflecting its status as a clinical-stage biopharmaceutical company. Key valuation metrics include the potential market size for Lanifibranor in NASH and the value of its strategic partnerships. Growth considerations include the successful completion of Phase III clinical trials and regulatory approval. Analyst consensus is influenced by the potential of Lanifibranor to address the growing NASH market and the company's ability to execute its clinical development and commercialization strategy. No buy or sell recommendations are made here.
What are the main risks for IVA?
The main risks for Inventiva S.A. include the uncertainty of clinical trial outcomes, regulatory hurdles, and competition from other companies developing NASH therapies. Clinical trial failures or regulatory delays could significantly impact the company's valuation and future prospects. Competition from larger pharmaceutical companies with greater resources also poses a risk. Additionally, the company's reliance on external funding and strategic partnerships exposes it to financial and operational risks.
What are the key factors to evaluate for IVA?
Inventiva S.A. (IVA) holds an AI score of 56/100 (moderate). Analysts target $16.50 (+330%). Not financial advice.
How frequently does IVA data refresh on this page?
IVA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IVA's recent stock price performance?
Inventiva S.A. (IVA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product candidate Lanifibranor with promising Phase IIb results. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IVA overvalued or undervalued right now?
Valuing Inventiva S.A. (IVA) requires multiple metrics. Analysts target $16.50 (+330%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IVA?
Before investing in Inventiva S.A. (IVA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Clinical trial outcomes are inherently uncertain.
- Market estimates are subject to change.